Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort

Summary Background Programmed cell death protein‐1‐targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real‐world cohort of patients with advanced hepa...

Full description

Saved in:

Bibliographic Details
Published in:	Alimentary pharmacology & therapeutics Vol. 49; no. 10; pp. 1323 - 1333
Main Authors:	Scheiner, Bernhard, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Koch, Sandra, Schwabl, Philipp, Hinrichs, Jan B., Waneck, Fredrik, Waidmann, Oliver, Reiberger, Thomas, Müller, Christian, Sieghart, Wolfgang, Trauner, Michael, Weinmann, Arndt, Wege, Henning, Trojan, Jörg, Peck‐Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias
Format:	Journal Article
Language:	English
Published:	England Wiley Subscription Services, Inc 01.05.2019 John Wiley and Sons Inc
Subjects:	Aged Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Apoptosis Austria Carcinoma, Hepatocellular - drug therapy Cell death Diarrhea Disease control Female Germany Hepatitis Hepatocellular carcinoma Humans Immunotherapy Liver cancer Liver Neoplasms - drug therapy Male Middle Aged Monoclonal antibodies Nivolumab - therapeutic use Original Pembrolizumab Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death Protein‐1 Targeted Immunotherapy for Hepatocellular Carcinoma Proteins Pruritus Retrospective Studies Safety Targeted cancer therapy Austria Germany
ISSN:	0269-2813, 1365-2036, 1365-2036
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!